Pulse Biosciences (NASDAQ:PLSE) Reaches New 1-Year High – Here’s What Happened

Pulse Biosciences, Inc (NASDAQ:PLSE) hit a new 52-week high during trading on Monday . The stock traded as high as $37.53 and last traded at $37.4220, with a volume of 39007 shares traded. The stock had previously closed at $35.13.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Finally, Canaccord Genuity Group began coverage on Pulse Biosciences in a research report on Thursday, June 4th. They set a “buy” rating and a $32.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.33.

Pulse Biosciences Stock Up 6.7%

The business has a 50-day moving average price of $27.65 and a 200-day moving average price of $22.84. The firm has a market capitalization of $2.60 billion, a P/E ratio of -33.96 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.05. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.25 million. As a group, sell-side analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, Director Robert W. Duggan acquired 660,233 shares of Pulse Biosciences stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $19.69 per share, with a total value of $12,999,987.77. Following the acquisition, the director owned 48,211,433 shares of the company’s stock, valued at approximately $949,283,115.77. The trade was a 1.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paul A. Laviolette bought 15,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $19.69 per share, for a total transaction of $295,350.00. Following the completion of the transaction, the chief executive officer owned 15,000 shares in the company, valued at $295,350. This represents a ? increase in their position. The SEC filing for this purchase provides additional information. Insiders own 74.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Portolan Capital Management LLC acquired a new stake in Pulse Biosciences in the 3rd quarter valued at $1,809,000. Brooklyn Investment Group grew its position in Pulse Biosciences by 330.7% in the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after acquiring an additional 100,081 shares during the period. Bank of America Corp DE grew its position in Pulse Biosciences by 8.2% in the first quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock valued at $18,698,000 after acquiring an additional 65,884 shares during the period. Argo Wealth Advisory LLC acquired a new position in Pulse Biosciences during the fourth quarter worth $387,000. Finally, Tudor Investment Corp ET AL acquired a new position in Pulse Biosciences during the fourth quarter worth $382,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.